K090101 Page /g/2

Bard Access Systems EQUISTREAM™ Hemodialysis Catheter Special 510(k) Premarket Notification

Section 5 - 510(k) Summary

Page 17 of 77

510(k) Summary 21 CFR 807.92(a)

EQUISTREAM™ Long-Term Hemodialysis Catheter Family Prepared January 14, 2009

FEB 1 0 2009

Submitter of 510(k) Premarket Notification: Bard Access Systems, Inc. (BAS) [Subsidiary of C.R. Bard, Inc.] Salt Lake City, Utah 84116 Phone: (801) 522-5651 (801) 522-5425 Fax:

General **Provisions**

Contact Person:

Jessica Agnello Regulatory Affairs Specialist

Device Trade Name: Device Generic Name:

EQUISTREAM™ Long-Term Hemodialysis Catheters

Trade Name:

HemoSplit®

Classification Name:

Common/Usual Name: Long-Term Hernodialysis Catheters 78 MSD-Catheter, Hemodialysis, Implanted

CFR Reference: Classification Panel: 21 CFR §876.5540(b)(1), @lass@III -Gastroenterology and Urology

Premarket Notification: See below

Predicate Device Name:	510(k)	Concurrence Date
	AND THE STATE OF THE WAR AND AND THE	1000-100-100-100-100-100-100-100-100-10
HemoSplit® Long-Term	K030020	June 16, 2003
Hemodialysis Catheter	K030020	Julie 10, 2003

Classification

Predicate

Device

21 CFR §876.5540(b)(1), Class III 78 MSD-Catheter, Hemodialysis, Implanted

Performance Standards

Performance standards have not been established by FDA under section 514 of the Federal Food, Drug and Cosmetic Act.

Intended Use

EQUISTREAM™ catheters are recommended for use in attaining short-term or long-term vascular access for hemodialysis, hemoperfusion, and apheresis treatments.

Indications for Use

The EQUISTREAM™ long-term hemodialysis catheter is indicated for use in attaining short-term or long-term vascular access for hemodialysis, hemoperfusion, and apheresis therapy. Access is attained via the internal jugular vein, external jugular vein, subclavian vein or femoral vein. Catheters greater than 40cm are intended for femoral vein insertion.

Technological Characteristics

Technological similarities between the subject **EQUISTREAM™** catheters and the predicate device remain identical. There are no new questions raised regarding safety or efficacy of the subject EQUISTREAM™ catheters.

K090101 Page 242

Bard Access Systems EQUISTREAM™ Hemodialysis Catheter Special 510(k) Premarket Notification Section 5 - 510(k) Summary

Page 18 of 77

Summary of Substantial Equivalence Based on the indications for use, technological characteristics, and safety and performance testing, the subject **EQUISTREAM™** catheters met the minimum requirements that are considered adequate for its intended use and is substantially equivalent in design, materials, sterilization, principles of operation and indications for use to current commercially available catheters/cited predicates.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Jessica Agnello Regulatory Affairs Specialist C. R. Bard, Inc. Bard Access Systems 605 North 5600 West SALT LAKE CITY UT 84116

FEB 1 0 2009

Re: K090101

Trade/Device Name: EQUISTREAM™ Long-Term Hemodialysis Catheter Family

Regulation Number: 21 CFR 876.5540

Regulation Name: Blood access device and accessories

Regulatory Class: III Product Code: MSD Dated: January 14, 2009 Received: January 15, 2009

Dear Ms. Agnello:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market the device, subject to the general controls provisions of Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. Please note: If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation, please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (240) 276-3150, or at its Internet address

http://www.fda.gov/cdrh/industry/support/index.html.

Singerely yours,

anine M. Morris

Acting Director, Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

K090101

Bard Access Systems EQUISTREAM™ Hemodialysis Catheter Special 510(k) Premarket Notification Section 4 - Indications for Use Statement

Page 15 of 77

510(k) Number (if known): 1090101

Device Name:

EQUISTREAM™ Long-Term Hemodialysis Catheter Family

Indications for Use:

The EQUISTREAM™ long-term hemodialysis catheter is indicated for use in attaining short-term or long-term vascular access for hemodialysis, hemoperfusion, and apheresis therapy. Access is attained via the internal jugular vein, external jugular vein, subclavian vein or femoral vein. Catheters greater than 40cm are intended for femoral vein insertion.

Prescription Use (Part 21 CFR §801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR §801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices

510(k) Number

: 00015